Synergistic antitumor effect of MK-1775 and CUDC-907 against prostate cancer
{{output}}
Due to the emergence of drug resistance, androgen receptor (AR)-targeted drugs still pose great challenges in the treatment of prostate cancer, and it is urgent to explore an innovative therapeutic strategy. MK-1775, a highly selective WEE1 inhibitor, is shown... ...